Carasent 과거 수익 실적

과거 기준 확인 0/6

Carasent의 수입은 연평균 -16.6%의 비율로 감소해 온 반면, Healthcare Services 산업은 수입이 연평균 6.8%의 비율로 증가했습니다. 매출은 연평균 33.6%의 비율로 증가해 왔습니다.

주요 정보

-16.6%

수익 성장률

-8.9%

EPS 성장률

Healthcare Services 산업 성장	12.5%
매출 성장률	33.6%
자기자본 수익률	-0.8%
순이익	-3.0%
다음 실적 업데이트	13 Feb 2025

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Carasent 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

LSE:0H9M 수익, 비용 및 수입 (NOK Millions )
날짜	수익	수익	G+A 비용
30 Sep 24	265	-8	157
30 Jun 24	254	-10	148
31 Mar 24	251	-56	150
31 Dec 23	244	-46	146
30 Sep 23	235	-64	117
30 Jun 23	227	-49	106
31 Mar 23	210	5	84
31 Dec 22	195	31	65
30 Sep 22	179	47	98
30 Jun 22	168	15	87
31 Mar 22	154	33	75
31 Dec 21	137	0	62
30 Sep 21	117	-33	99
30 Jun 21	98	-21	89
31 Mar 21	83	-46	80
31 Dec 20	71	-38	73
30 Sep 20	64	-14	26
30 Jun 20	58	-4	24
31 Mar 20	52	3	23
31 Dec 19	48	3	22
30 Sep 19	44	2	20
30 Jun 19	40	0	19
31 Mar 19	35	-3	18
31 Dec 18	24	-7	15
30 Sep 18	14	12	16
30 Jun 18	6	18	12
31 Mar 18	0	19	7
31 Dec 17	0	20	6
30 Sep 17	25	128	-28
30 Jun 17	79	131	-4
31 Mar 17	136	139	22
31 Dec 16	194	142	50
30 Sep 16	205	3	10
30 Jun 16	234	56	51
31 Mar 16	259	56	69
31 Dec 15	305	61	94
30 Sep 15	322	-31	131
30 Jun 15	307	-80	100
31 Mar 15	314	-84	100
31 Dec 14	294	-79	91
30 Sep 14	255	2	64
30 Jun 14	248	2	63
31 Mar 14	246	3	66
31 Dec 13	254	5	72

양질의 수익: 0H9M 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 0H9M 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 0H9M 은(는) 수익성이 없으며 지난 5년 동안 연간 16.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 0H9M 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 0H9M 은(는) 수익성이 없어 지난 해 수익 성장을 Healthcare Services 업계( 3.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 0H9M 현재 수익성이 없기 때문에 마이너스 자본 수익률( -0.84% )을 갖습니다.

Carasent 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Recent updates

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Carasent Asa Approves Dividend

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Chief Executive Officer recently bought kr96k worth of stock

High number of new and inexperienced directors

Chief Executive Officer recently bought kr97k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기